Delivery Order SPE2DB24D1007-SPE2DB25FCCXF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ibrance 100 mg capsules (21-count packaging) at a ceiling value of $8,122.48 under a firm fixed-price contract. This is a non-set-aside competitive award with a completion date of September 2, 2025, and represents a child contract under AmerisourceBergen's larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This non-set-aside, competitively awarded contract specifies an ultimate completion date of August 28, 2025, and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on July 21, 2025, with an ultimate completion date of August 11, 2025. The contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitively awarded procurement from the company's existing pharmaceutical supply agreement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,123.96 to supply Ibrance 75 mg tablets (quantity 7) with a firm fixed price structure. This non-set-aside, competitively awarded contract is designated as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,247.92 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count packaging) under a firm fixed price contract. The contract was competitively awarded without a set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ibrance 125 mg tablets (7-count) under a firm fixed-price contract with a ceiling value of $8,118.08 and an ultimate completion date of September 8, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (quantity 7) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the prime contractor, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ibrance is a prescription oncology medication used...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCXFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply vehicle, which supports military healthcare systems and other federal medical procurement needs globally. The company's IDC encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. Ibrance is an oncology medication used in cancer treatment, reflecting AmerisourceBergen's role in supplying critical specialty pharmaceuticals to the Defense Health Agency and other government healthcare systems. This transaction exemplifies the company's continued participation in DLA's medical supply chain operations and its capability to deliver essential pharmaceutical products to support federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 8/19/25 |